Trials of commercial reagents in anion-exchange coagulation procedures: ortho diagnostics.
The suitability of Ortho Diagnostics one-stage prothrombin time (PT) reagent (Ortho Brain Thromboplastin) and activated partial thromboplastin (aPTT) reagent (Activated Thrombofax) has been evaluated for use in conjunction with the anion-exchange heparin removal maneuver. The PT/HR and aPTT/HR are tests used to follow the anticoagulant influence of coumarins when heparin also is being administered. After establishing a coumarin therapeutic range for Activated Thrombofax, a parallel trial was conducted with Ortho Brain Thromboplastin on coumarin-treated patient plasmas. Determinations also were made after heparin (0.2 mu/mL) was added and then removed by ECTEOLA microchromatography columns. Ortho Brain Thromboplastin was found to induce a shortening bias associated with a spurious improvement in the precision of tests run on anion-exchange treated plasmas that potentially could result in coumarin overdosage. The systematic error did not appear to result either from protracted incubation or the activation of prekallikrein, high molecular weight kininogen, Factor XI or XII. This reagent was found to perform appropriately with plasma not exposed to ECTEOLA. Activated Thrombofax gave reliable and reproducible results before and after heparin removal. This aPTT reagent could be used in the aPTT/HR anticoagulant surveillance scheme.
D001780:Blood Coagulation Tests; D002852:Chromatography, Ion Exchange; D005188:False Negative Reactions; D006493:Heparin / Q000032:analysis; D006801:Humans; D007202:Indicators and Reagents; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time; D013223:Statistics as Topic; D014859:Warfarin / Q000627:therapeutic use
D007202:Indicators and Reagents; D014859:Warfarin; D006493:Heparin